Endo’s Bleak Financial Reality May See Hope In Spring Amid Potential Restructuring
Generic And Injectables Products Saw Competition And Revenue Decrease
Endo’s generic and injectable segments struggled last year, with even lower projections for 2024, but potential financial restructuring may help the company rise from the ashes.
